DOCSLIB.ORG

Genetic Engineering and Biotechnology 4/1997

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Genetic Engineering and Biotechnology 4/1997 OCCASION This publication has been made available to the public on the occasion of the 50th anniversary of the United Nations Industrial Development Organisation. DISCLAIMER This document has been produced without formal United Nations editing. The designations employed and the presentation of the material in this document do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations Industrial Development Organization (UNIDO) concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries, or its economic system or degree of development. Designations such as “developed”, “industrialized” and “developing” are intended for statistical convenience and do not necessarily express a judgment about the stage reached by a particular country or area in the development process. Mention of firm names or commercial products does not constitute an endorsement by UNIDO. FAIR USE POLICY Any part of this publication may be quoted and referenced for educational and research purposes without additional permission from UNIDO. However, those who make use of quoting and referencing this publication are requested to follow the Fair Use Policy of giving due credit to UNIDO. CONTACT Please contact [email protected] for further information concerning UNIDO publications. For more information about UNIDO, please visit us at www.unido.org UNITED NATIONS INDUSTRIAL DEVELOPMENT ORGANIZATION Vienna International Centre, P.O. Box 300, 1400 Vienna, Austria Tel: (+43-1) 26026-0 · www.unido.org · [email protected] EMERGING TECHNOLOGY SERIES 4/1997 Genetic Engineering and Biotechnology UNITED NATIONS INDUSTRIAL DEVELOPMENT ORGANIZATION Vienna, 1998 TO OUR READERS EMERGING TECHNOLOGY SERIES: Under the leadership of the new Director-General of UNIDO, who took office on 8 December 1997, a new programmatic GENETIC ENGINEERING approach for the Organization was developed, with services AND BIOTECHNOLOGY designed to help recipient countries solve their industrial development problems in the changing global economic environment. Ten packages of services that encompass the 1997/4 following areas of activities will constitute the core of future UNIDO services: Industrial Governance; Industrial Export Capacity-Building; Industrial Information Networking; International Industrial Partnerships; Quality and Certification for Industrial Competitiveness; Cleaner Production and Environment; Efficient Energy Development; Agro-related Industries Development; Local Industrial Development; and CONTENTS Women Entrepreneurship Development. These 1nte9rated packages of services are designed for both the public and SPECIAL ARTICLE: private sectors. Africa is the developing region where the transformed UNIDO Progressing Public-Private Sector and its new services will be first put to test. The services are Partnerships in International Agricultural designed to meet most demands of developing countries in Research and Development rapidly changing global economic conditions. Once they are by Clive James, Chair, /SAAA Board of adapted and customized to attend to the specific needs of an individual country, these services will eventually promote the Directors three E's of the UNIDO Business Plan: Economy, Environment and Employment by promoting a competitive economy; NEWS AND EVENTS creating employment; and protecting the environment. COUNTRY NEWS In this spirit, UNIDO has recently signed an agreement with the United Nations Conference on Tracfe and Development (UNCTAD), in which the complementary roles of the two RESEARCH organizations in investment and technology promotion and the related area of small and medium enterprise development are APPLICATIONS spelled out. Thus, UNIDO and UNCTAD have forged a new strategic alliance to boost investment in developing countries. The alliance harnesses the two organizations' comparative PATENTS AND INTELLECTUAL advantages to maximize delivery of services and avoid PROPERTY RIGHTS duplication, as part of the United Nations' efforts to pool the resources of its agencies. BOOKS, JOURNALS, REVIEWS AND BIOINFORMATICS While UNIDO will focus on advice and assistance on industrial sector issues and investment and technology promotion UNIDO's Emerging Technology Series: Genetic support, UNCTAD will concentrate on policy issues affecting Engineering and Biotechnology is established as a investment promotion, including the regulatory and institutional mechanism of current awareness to monitor developments in the genetic engineering and framework for investment. These arrangements will also biotechnology sector and inform governments, include the formation of new partnerships between the two industry and academia, primarily in developing organizations and the private sector of industry. Joint activities countries. will take place at the country and global levels. The publication is issued four times a year and distributed free of charge to readers in developing To attract investment and technology transfer to Africa, UNIDO countries. It is not a formal document and has offers a number of services to individual states. These include been reproduced without formal editing. Opinions Build-Operate-Transfer (BOT) strategies, review and advice on expressed here do not necessarily reflect the views of UNIDO. Mention of the names of firms legal framework, strengthening investment and technology and commercial products does not imply an related institutions; advice on organization, procedures, endorsement by UNIDO. Copyrighted material networking and operation set-up of national investment reproduced in this publication may be quoted only promotion agencies, preparation of promotional material, with permission of the journals concerned. Other material may be quoted or reproduced without organizing promotional events such as Investment Promotion further permission. Due acknowledgement is Fora and Techmarts, networking and subcontrating; and requested. finally, on-the-job training for investment promotion personnel in UNIDO's Investment Promotion Offices in developed countries. Investment promotion events play a major role in Compiled and edited: Diana Rhind laying the groundwork for new projects, not only for individual Editorial Board: Y. Maruno, V. Podshibyakin; G. Tzotzos; B. Sugavanam; Z. Cziser states, but also for regions. Published in 1998 by the United Nations Industrial Readers will be pleased to hear that the New Delhi component Development Organization (UNIDO) of the International Centre for Genetic Engineering and Vienna International Centre P.O. Box 300 Biotechnology (ICGEB), now has a new Director, malaria A-1400 Vienna researcher V1rander Singh Chauhan, who hopes to spur Austria modernization of the Centre under his leadership. Tel.: (43-1)21131-3736; Fax: (43-1)21131-6843 e-mail: [email protected] In the previous issue of Genetic Engineering and Biotechnology, on page 21 we should have given the following information on Brazil's biotechnology organization: Brazilian entrepreneurial biotechnology is represented by ABRABI, the Brazilian Association of Biotechnology Enterprises, which collects companies, incubators and research centres. Among these is Biominas Foundation (mentioned in our published text), which is one of the foremost members of ABRABI. The Biominas President, Guilherme Emrich, is a close associate and Vice-President of ABRABI. The President of ABRABI itself is Antonio Paes de Carvalho. We sincerely apologize for any inconvenience caused by this incomplete information. The address of ABRABI is as follows: ABRABI-Brazilian Association of Biotechnology Enterprises Dr. Antonio Paes de Carvalho, M.D., Ph.D., President Polo Bio-Rio-Cidade Universitaria Rio de Janeiro-RJ Brazil 21.941-590 Tel: (+55-21) 290-5839 Fax: (+55-21) 260-7920 E-mail: [email protected] Genetic Engineering and Biotechnology J99714 .CONTENTS Page Page A. SPECIAL ARTICLE ....................... 1 Europe and the biotechnology gap .......... 45 World environment ...................... 45 PROGRESSING PUBLIC-PRJVATE SECTOR PARTNER­ Biopharmaceuticals set for change . ..... 46 SHIPS IN INTERNATIONAL AGRICULTURAL RESEARCH AND DEVELOPMENT ••••••••••••• 1 C. COUNTRY NEWS ..........••••••••••.... 47 B. NEWS AND EVENTS ••••••••••••••••..... 37 Austria .................................. 47 EC urges Austria to end modified maize ban .. 47 UN and other organizations' news ••••••••••. 37 Brazil ................................... 47 Biodiversity indicators and implementation BIOLATINA 98 ......................... 47 targets: Global Diversity Forum prepares for Canada .................................. 47 United Nations General Assembly review .. 37 Canadian biotech regulations ............... 47 Boosting seed supply ..................... 37 Biotechnology boom ..................... 4 7 Cassava bacterial blight: a major threat to Help for Cuban Biopharmaceuticals ......... 4 7 production ........................... 38 China ................................... 48 Regulatory issues •.•..........•..••••••••• 38 US China pact yields new cancer vaccines .... 48 USDA amends regulations for GMOs ........ 38 Biotech key to self-sufficiency in China ...... 48 Blunt pharming talk ..................... 38 Costa Rica ............................... 48 Microbial biotech regulations set ............ 38 Indena, INBio enter collaboration ........... 48 New US regulatory framework emerges for European Union ........................... 48 genetics ............................
Load more

Recommended publications
  • PATENTES, DESENHOS INDUSTRIAIS, CONTRATOS, PROGRAMAS DE COMPUTADOR, INDICAÇÕES GEOGRÁFICAS O REVISTA DA PROPRIEDADE INDUSTRIAL N 1964 26 De Agosto De 2008
    PATENTES, DESENHOS INDUSTRIAIS, CONTRATOS, PROGRAMAS DE COMPUTADOR, INDICAÇÕES GEOGRÁFICAS o REVISTA DA PROPRIEDADE INDUSTRIAL N 1964 26 de Agosto de 2008 SEÇÃO I REPÚBLICA FEDERATIVA DO BRASIL Presidente Luís Inácio Lula da Silva MINISTÉRIO DO DESENVOLVIMENTO, INDÚSTRIA E COMÉRCIO EXTERIOR Ministro do Desenvolvimento, Indústria e Comércio Exterior Miguel João Jorge Filho INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL PRESIDENTE PARANÁ Jorge de Paula Costa Ávila Chefe: Renee Fernando Senger Pernambuco Rua Marechal Deodoro, 344, 16º andar Universitária Federal de Pernambuco - UFPE VICE-PRESIDENTE Ademir Tardelli Edifício Atalaia, Centro, Curitiba - PR Av. Prof. Moraes Rego, 1235 – Campus Universitário CEP: 80010-909 Bairro - Engenho do Meio CHEFE DE GABINETE Telefone/Fax: (0XX-41) 3322-4411 Recife - PE - CEP: 50670-920 Josefina Sales de Oliveira RIO GRANDE DO SUL Tel/Fax:(0XX-81) 3453-8145 e 3271-1223 Chefe: Vera Lúcia de Seixas Grimberg Piauí DIRETORIA DE ARTICULAÇÃO E INFORMAÇÃO TECNOLÓGICA Rua Sete de Setembro, 515 – 5º andar - Centro Av. João XXIII, n° 865 Marco Antônio Lima Porto Alegre - RS - CEP: 90010-190 Espaço Cidadania Telefone/Fax.: (0XX-51) 3226-6909 e 3226-6422 Teresina - PI - CEP: 64049-010 PROCURADORIA GERAL SÃO PAULO Tel.:(0XX-86) 3235-9616/3218-1838 Mauro Sodré Maia Chefe: Maria dos Anjos Marques Buso Fax:(0XX-86) 3218-1838 DIRETORIA DE PATENTES Rua Tabapuã, 41 - 4º andar - Itaim-Bibi Rio Grande do Norte Carlos Pazos Rodrigues São Paulo - SP - CEP: 04533-010 SECRETÁRIA DO DESENVOLVIMENTO ECONÔMICO – DIRETORIA DE MARCAS Telefone/Fax:
    [Show full text]
  • Immuno-Oncology Drug Development Workshop Hyatt Regency Washington on Capitol Hill Columbia A&B Ballroom Washington, DC October 13 - 14, 2016
    Immuno-Oncology Drug Development Workshop Hyatt Regency Washington on Capitol Hill Columbia A&B Ballroom Washington, DC October 13 - 14, 2016 Workshop Co-Chairs Maitreyee Hazarika, MD, Medical Officer, Division of Oncology Products 2, Office of Hematology Oncology Products, Center for Drug Evaluation and Research, FDA Dr. Hazarika is a Senior Medical Officer in the Melanoma and Sarcoma Team in the Division of Oncology Products 2 (DOP2) of the Office of Hematology and Oncology Products (OHOP) in the Center for Drug Evaluation and Research (CDER) of the United States Food and Drug Administration (FDA). As a regulatory reviewer, she has reviewed new molecular entities for marketing approvals in solid tumors and hematological malignancies, which have included immunotherapies, targeted kinase inhibitors, immunomodulators and folate analog metabolic inhibitors. She has presented FDA review findings as a speaker at oncology drug advisory committee meetings and has authored manuscripts presenting summaries on FDA drug approvals. In addition to the regulatory experience at FDA, she has experience in global clinical drug development while an Associate Medical Director, Clinical Development at Celgene International and also provided consulting services as a subject matter expert in oncology and on regulatory and clinical aspects of pharmaceutical drug development while a Principal Consultant at Parexel Consulting. Dr. Hazarika received her MBBS and MD degrees in India and completed her internship and residency in Internal Medicine and fellowship in Medical Oncology and Hematology at the New York University School of Medicine. As a fellow, she co-authored a book chapter while active in clinical research in ovarian cancer. Marc Theoret, MD, Lead Medical Officer, Division of Oncology Products 2, Office of Hematology Oncology Products, Center for Drug Evaluation and Research, FDA Dr.
    [Show full text]
  • Ste28.Pdf(469KB)
    Shiri Breznitz PhD Candidate, Dept. of Geography, University of Cambridge Email - [email protected] Research: My main focus is regional economic development. I am particularly interested in university-industry relationships and their influence on local economies. From Ivory Tower to Industrial Promotion: The Case of Yale University and the Biotechnology Cluster in New Haven, Connecticut Shiri Breznitz 28 Science, Technology and the Economy Program (STE) Working Papers Series STE-WP - 28 - 2005 From Ivory Tower to Industrial Promotion: The Case of Yale University and the Biotechnology Cluster in New Haven, Connecticut Shiri Breznitz Department of Geography University of Cambridge STE – WP 28 May 2005 This is a report on a research project conducted as part of the activities of the Science Technology and the Economy Program, (STE), at the Samuel Neaman Institute for Advanced Studies in Science and Technology. This research was carried out as part of a larger project on the Role of the University in Regional Economic Development. The author is grateful to the MIT Industrial Performance Center (IPC), the Cambridge Political Economy Society Trust, and the STE program at the Samuel Neaman Institute, for their generous support of this research. This paper presents the author’s own view and not that of the Samuel Neaman Institute for Advanced Studies in Science and Technology or any members of its staff. From Ivory Tower to Industrial Promotion: The Case of Yale University and the Biotechnology Cluster in New Haven, Connecticut Abstract In 2001 Ernst & Young ranked the state of Connecticut seventh in the nation with respect to the number of biotech firms operating within its borders relative to its population (Ernst & Young, 2001).
    [Show full text]
  • Fiscal Year 2006/2007 Office of Research University of South Florida
    REPORT OF RESEARCH ACTIVITIES Fiscal Year 2006/2007 Office of Research University of South Florida December 2007 Office of Research University of South Florida 30338 USF Holly Drive Tampa, Florida 33620-3033 Phone: 813-974-5570 Fax: 813-974-3348 Email: [email protected] This document is also available on the USF Office of Research Web site at www.research.usf.edu FY06/07 TABLE OF CONTENTS SECTION 1 . 1-6 z Contact Information { Office of Research { Research Technologies { Research Resources { Sponsored Research { Research Integrity and Compliance { Comparative Medicine { Technology Development { Patents & Licensing { USF Research Foundation z Office of Research Web Site http://www.research.usf.edu z Research Activity Reports http://reports.research.usf.edu SECTION 2 . 7- 50 z Awards Data SECTION 3 . 51-186 z Project Awards: Detailed Funding SECTION 4 . 187-202 z Non-Project Awards: Detailed Funding SECTION 5 . 203-218 z Internal Awards Programs { Program Overview { Research Council Members { 2006 - 2007 Awards Table { Five-Year Summary { Detailed Funding SECTION 6 . 219-225 z Proposal Data UNIVERSITY OF SOUTH FLORIDA OFFICE OF RESEARCH REPORT OF RESEARCH ACTIVITIES FISCAL YEAR 2006/2007 SECTION 1 CONTACTS 1 2 Organizational and Contact Information as June 30, 2007 Office of Research Chang, Ph.D., Robert [email protected] (813) 974-5481 Vice President for Research Pope, Priscilla [email protected] (813) 974-2897 Associate Vice President Casto, Ph.D., Rod [email protected] (813) 974-1082 Associate Vice President
    [Show full text]
  • Orphan Drug Dummy File
    Orphan Drug Designations and Approvals List as of 09‐01‐2016 Governs October 1, 2016 ‐ December 31, 2016 Row Contact Generic Name Trade Name Designation Date Designation Num Company/Sponsor 1 1. Prevention of secondary carnitine deficiency in valproic acid toxicity 2. Treatment of secondary carnitine deficiency in Sigma-Tau levocarnitine Carnitor 11/15/1989 valproic acid toxicity Pharmaceuticals, Inc. 2 1. Treatment of graft versus host disease in patients receiving bone marrow transplantation 2. Prevention of graft versus host disease in patients receiving Pediatric thalidomide n/a 9/19/1988 bone marrow transplantation Pharmaceuticals, Inc. 3 A Diagnostic for the management Advanced Imaging Theranost 68 Ga RGD n/a 10/1/2014 of Moyamoya disease (MMD) Projects, LLC (AIP) 4 Cadila heat killed Mycobacterium w Pharmaceuticals immunomodulator Cadi Mw 9/3/2004 Active tuberculosis Limited, Inc. 5 Adjunct to cytokine therapy in the treatment of acute myeloid Histamine Ceplene 12/15/1999 leukemia. EpiCept Corporation 6 Adjunct to surgery in cases of rh-microplasmin, ocriplasmin Jetrea 3/16/2004 pediatric vitrectomy ThromboGenics Inc. 7 Adjunct to the non-operative management of secreting cutaneous fistulas of the stomach, duodenum, small intestine (jejunum and ileum), or Ferring Laboratories, Somatostatin Zecnil 6/20/1988 pancreas. Inc. Page 1 of 377 Orphan Drug Designations and Approvals List as of 09‐01‐2016 Governs October 1, 2016 ‐ December 31, 2016 Row Contact Generic Name Trade Name Designation Date Designation Num Company/Sponsor 8 Adjunct to whole brain radiation therapy for the treatment of brain metastases in patients with Allos Therapeutics, efaproxiral n/a 7/28/2004 breast cancer Inc.
    [Show full text]
  • Margin Stocks, Notice 97-22
    F e d e r a l R e s e r v e B a n k OF DALLAS ROBERT D. MCTEER, JR. _____ p r e s i d e n t DALLAS, TEXAS AND CHIEF EXECUTIVE OFFICER 75265-5906 March 10, 1997 Notice 97-22 TO: The Chief Executive Officer of each member bank and others concerned in the Eleventh Federal Reserve District SUBJECT Over-the-Counter (OTC) Margin Stocks DETAILS The Board of Governors of the Federal Reserve System has revised the list of over- the-counter (OTC) stocks that are subject to its margin regulations, effective February 10, 1997. Included with the list is a listing of foreign margin stocks that are subject to Regulation T. The foreign margin stocks listed are foreign equity securities eligible for margin treatment at broker- dealers. The Board publishes complete lists four times a year, and the Federal Register announces additions to and deletions from the lists. ATTACHMENTS Attached are the complete lists of OTC stocks and foreign margin stocks as of February 10, 1997. Please retain these lists, which supersede the complete lists published as of February 12, 1996. Announcements containing additions to and deletions from the lists will be provided quarterly. MORE INFORMATION For more information regarding marginable OTC stock requirements, please contact Eugene Coy at (214) 922-6201. For additional copies of this Bank's notice and the complete lists, please contact the Public Affairs Department at (214) 922-5254. Sincerely yours, yf f a * / ' . For additional copies, bankers and others are encouraged to use one of the following toll-free numbers in contacting the Federal Reserve Bank of Dallas: Dallas Office (800) 333 -4460; El Paso Branch Intrastate (800) 592-1631, Interstate (800) 351-1012; Houston Branch Intrastate (800) 392-4162, Interstate (800) 221-0363; San Antonio Branch Intrastate (800) 292-5810.
    [Show full text]
  • [ Emc-Lusinnufll'lergcrta'rgets
    US 20070255633Al (19) United States (12) Patent Application Publication (10) Pub. N0.: US 2007/0255633 A1 Kridel (43) Pub. Date: NOV. 1, 2007 (54) SYSTEMS AND METHODS FOR INVESTING (52) US. Cl. ....................................................... .. 705/35 (76) Inventor: FIVJigiam J. Kridel, New York, NY (57) ABSTRACT The present invention discloses systems and methods for Correspondence Address? creating and managing ?nancial instruments and indexes PAUL’ HASTINGS’ JANOFSKY & WALKER comprised of securities for companies in subsectors of the LLP economy. These ?nancial instruments alloW investment in R0' BOX 919092 subsectors of the economy Will still being able to minimize SAN DIEGO CA 92191-9092 ’ risk by diversi?cation. The indexes serve as benchmarks for (21) App1_ NO; 11/465,768 companies in the subsectors of the economy. A procedure may be used to identify the securities to include in the (22) Filed: Allg- 18, 2006 ?nancial instruments. This procedure may include (a) iden _ _ tifying securities for companies in a sector of the economy; Related U's‘ Apphcatlon Data (b) limiting the identi?ed securities to those for companies (60) Provisional application No. 60/778,492, ?led on Mar. in a SubSeCIOr Of the SBCIOI‘ Of the economy; (0) applying 1, 2006. focus rules to further limit the identi?ed securities to those _ _ _ _ for companies Who are focused in the subsector of the Pubhcatlon Classl?catlon economy; and (d) limiting the securities included in the (51) Int, Cl, ?nancial instrument or index to those that satisfy other G06Q 40/00 (2006.01) objective criteria. ETF RULE. SET->| APPLICATION’ ' "1 _.
    [Show full text]
  • Teligent Annual Report 2020
    Teligent Annual Report 2020 Form 10-K (NASDAQ:TLGT) Published: April 28th, 2020 PDF generated by stocklight.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-08568 TELIGENT, INC. (Formerly IGI Laboratories, Inc.) (Exact name of registrant as specified in its charter) Delaware 01-0355758 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 105 Lincoln Ave., Buena, New Jersey 08310 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code (856) 697-1441 Securities registered pursuant to Section 12(b) of the Exchange Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value Per Share TLGT The Nasdaq Stock Market Securities registered pursuant to Section 12(g) of the Exchange Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ¨ No x Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes ¨ No x Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Shire R&A 01 Cover
    Shire Pharmaceuticals Group plc Shire Pharmaceuticals Group plc Annual review and summary financial statement 2001 Shire is proud of the part it plays in developing products which help people live their lives to the full. Shire, an international specialty pharmaceutical company, has a strategic focus on three therapeutic areas: central nervous system disorders, oncology and anti-infectives. It also has two platform technologies: advanced drug delivery and biologics. Our global sales and marketing infrastructure has an established product portfolio. Shire has its own marketing subsidiaries in the US, Canada, the UK and the Republic of Ireland, France, Germany, Italy and Spain, with plans to add Japan by 2004. We cover other pharmaceutical markets indirectly through distributors. Our interests in the Pacific Rim are managed through our regional office in Singapore. Shire has a risk-balanced R&D portfolio with clear focus on future product needs. Our global research and development expertise supported by in-licensing has, to date, successfully provided 20 marketed products, while the current pipeline of 24 projects includes 12 that are either in or post Phase II. To enhance the potential for future growth, Shire follows two approaches, firstly, to start projects in-house through research and advanced drug delivery and secondly to in-license projects and products on reasonable commercial terms, and then to develop and launch them. This broad approach strengthens Shire’s strategy and takes account of ongoing changes that are taking place in the industry. During the past seven years, we have completed six mergers and acquisitions and whereas we continue to evaluate M&A opportunities that offer a good strategic fit and add shareholder value, our priority is in-licensing more projects and products.
    [Show full text]
  • United States Securities and Exchange Commission Washington, D.C
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement ¨ Definitive Additional Materials ¨ Soliciting Material Under Rule 14a-12 IGI Laboratories, Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): x No fee required. ¨ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. 1) Title of each class of securities to which transaction applies: 2) Aggregate number of securities to which transaction applies: 3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): 4) Proposed maximum aggregate value of transaction: 5) Total fee paid: ¨ Fee paid previously with preliminary materials. ¨ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing: 1) Amount previously paid: 2) Form, Schedule or Registration Statement No: 3) Filing party: 4) Date Filed: IGI LABORATORIES, INC.
    [Show full text]
  • High Probability of Long-Term Survival in 2-Year Survivors of Autologous Hematopoietic Cell Transplantation for AML in first Or Second CR
    Bone Marrow Transplantation (2011) 46, 385–392 & 2011 Macmillan Publishers Limited All rights reserved 0268-3369/11 www.nature.com/bmt ORIGINAL ARTICLE High probability of long-term survival in 2-year survivors of autologous hematopoietic cell transplantation for AML in first or second CR NS Majhail1,2, R Bajorunaite3, HM Lazarus4, Z Wang3, JP Klein3, MJ Zhang3 and JD Rizzo3 1Center for International Blood and Marrow Transplant Research, Minneapolis, MN, USA; 2Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN, USA; 3Center for International Blood and Marrow Transplant Research, Milwaukee, WI, USA and 4Division of Hematology and Oncology, University Hospitals Case Medical Center, Cleveland, OH, USA We describe the long-term outcomes of autologous Introduction hematopoietic cell transplantation (HCT) for 315 AML patients in first or second complete remission (CR). All After attainment of an initial remission, patients with AML patients were in continuous CR for X2 years after HCT. can receive consolidation therapy with either chemotherapy Patients were predominantly transplanted in CR1 (78%) or hematopoietic cell transplantation (HCT) based on and had good or intermediate cytogenetic risk disease various prognostic factors (for example, age, performance (74%). Median follow-up of survivors was 106 (range, status and cytogenetics). In general, patients with favorable 24–192) months. Overall survival at 10 years after HCT prognostic features receive consolidation chemotherapy was 94% (95% confidence intervals, 89–97%) and 80% only, whereas those with high-risk disease and an (67–91%) for patients receiving HCT in CR1 and CR2, acceptable risk of treatment-related morbidity and mortality respectively. The cumulative incidence of relapse at 10 are offered allogeneic HCT.
    [Show full text]
  • Orphan Drug Designations and Approvals List As of 12-02-2013 Governs January 1, 2014
    Orphan Drug Designations and Approvals List as of 12‐02‐2013 Governs January 1, 2014 ‐ March 31, 2014 Row Designation Generic Name Trade Name Orphan Designation Contact Company/Sponsor Num Date Treatment of Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone B‐cell Lymphoma of Mucosa‐ Associated Lymphoma Tissue (MALT), and Nodal Marginal Zone Lymphoma (Collectively Indolent B‐cell Non‐Hodgkin's 1 bendamustine hydrochloride Treanda 11/26/2013 Lymphoma) Cephalon, Inc. Treatment of subjects at risk of developing myelosuppression after a radiological or nuclear 2 Filgrastim Neupogen 11/20/2013 incident Amgen, Inc. adeno‐associated viral vector containing the human NADH Treatment of Leber Hereditary 3 Dehydrogenase 4 Gene n/a 11/20/2013 Optic Neuropathy Gen Sight Biologics Treatment of liver transplant recipients with reestablished fibrosis to delay the progression to cirrhosis and 4 emricasan n/a 11/20/2013 end stage liver disease Conatus Pharmaceuticals Inc. Page 1 of 262 Orphan Drug Designations and Approvals List as of 12‐02‐2013 Governs January 1, 2014 ‐ March 31, 2014 5‐((4‐bromo‐2‐ fluorophenyl)amino)‐4‐fluoro‐N‐(2‐ hydroxyethoxy)‐1‐methyl‐1H‐ Treatment Stage IIB‐IV Novartis Pharmaceuticals 5 benzo[d]imidazole‐6‐carboxamide n/a 11/19/2013 melanoma. Corporation Treatment of Hepatitis Delta 6 Lonafarnib n/a 11/19/2013 Virus (HDV)infection Eiger Biopharmaceuticals, Inc. Treatment in Stage IIB‐IV melanoma positive for the Novartis Pharmaceuticalues 7 MEK162
    [Show full text]